A European compassionate use and named patient basis for the treatment of neuroendocrine tumours
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Expanded access; Therapeutic Use
- 17 Nov 2017 According to an Advanced Accelerator Applications media release, in an compassionate program 1857 patients were participating from 67 centres in Europe.
- 31 Aug 2017 According to an Advanced Accelerator Applications media release, an European compassionate program were participating 1800 patients from 62 centres at 31 July 2017.
- 25 Jul 2017 New trial record